Petvivo Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQX
PetVivo Holdings reported increased revenues for Q1 2027, but faces substantial doubt regarding its ability to continue as a going concern due to ongoing net losses and accumulated deficit.
OQX
PetVivo Holdings, Inc. reported increased revenue driven by new product sales but saw a wider net loss for Q2 2026, alongside significant debt conversions and ongoing going concern doubts.
OQX
PetVivo Holdings, Inc. announced a significant increase in revenue for the quarter ended June 30, 2025, driven by new product sales, while also securing $5 million in Series B preferred stock funding to bolster liquidity.
OQX
PetVivo Holdings reports a slight decrease in revenue for the third quarter of fiscal year 2025, while implementing cost-cutting measures to reduce operating expenses.
OQX
PetVivo Holdings, Inc. reported its financial results for the quarter ended September 30, 2024, showing a decrease in net losses compared to the same period last year, while continuing to focus on commercializing its lead product, Spryng.
OQX
PetVivo Holdings reported a net loss of $2.047 million for the quarter ended June 30, 2024, while navigating a delisting from the Nasdaq stock market.
OQX
PetVivo Holdings, Inc. reports increased revenue for the third quarter of 2024, but continues to experience net losses and working capital challenges.